MRK vs ZBH
Merck & Co. vs Zimmer Biomet — AI-powered side-by-side comparison
| Metric | MRK | ZBH |
|---|
| AI Score |
70
|
69
|
| Price |
$130.34
|
$97.22
|
| P/E Ratio |
103.53×
|
23.54×
|
| ROE |
34.7%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.4%
|
69.9%
|
| Debt / Equity |
1.29×
|
0.59×
|
| Dividend Yield |
2.6%
|
1.0%
|
| RSI (14) |
64.5
|
63.1
|
| Beta |
0.207
|
0.462
|
| Expected Upside |
—
|
+3.7%
|
AI Committee View
Current Innellis committee reasoning for MRK versus ZBH.
MRK leads by 1 points.
MRK scores 70/100 (Buy) versus ZBH at 69/100 (Buy).
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
ZBH Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical